12 results
To improve the response rate to treatment of severe acute GVHD (grade II-IV with gut involvement ) by adding infusion of Mesenchymal Stroma Cells to standard high dose prednisolone.
To evaluate the efficacy and safety of eASCs compared to placebo for the treatment of complex fistulas in Crohn*s disease over a 24- and 104-week period.
To assess the safety (incidence of drug-related adverse events) and efficacy of allogeneic ASCs for the treatment of complex perianal Crohn*s fistulas compared to placebo.
The primary efficacy endpoint is treatment success in the therapy for mild to moderate Crohn*s disease with fisultas defined by: - A reduction of at least 50% in the number of draining fistulas at both week 4 and week 8
Primary Objective:• To determine the safety and feasibility of intracoronary allogeneic, immuno-selected, bone marrow-derived Stro3 MPC delivery in the treatment of subjects with STEMI undergoing PCI of the LAD coronary artery.Secondary Objectives…
Primary objective* To improve the response rate to treatment of severe steroid-refractory acute GvHD grade II-IV (with gut and/or liver involvement) by early addition of MSC to standardized second line treatmentSecondary objectives* To study the…
Primary Objective: To investigate whether intramuscular administration of allogeneic MSCs is safe and potentially effectiveSecondary Objective: To investigate the potential of various markers related to inflammation, angiogenesis, and…
The idea behind this study is to show that stem cell therapy is not just effective and safe but also an accessible, feasible and economically sound therapeutic option for patients with IHD and severe heart failureThe present aim is to perform at…
Development of mesenchymal stromal cell therapy to halt the progression of emphysema.
To investigate whether in patients with peripheral vascular complications related to SSc, intramuscular allogeneic BM-MSC therapy is feasible, safe and potentially effective. We expect that the proposed trial will allow us to come to a go-no go…
The primary objective is:to demonstrate the efficacy of 2 infusions (intravenous [i.v.]) of HepaStem at 1.0 million of cells/kg body weight (BW) (7 days apart) on the overall survival proportion at 90 days post first infusion.The secondary…
Primary objectives:Evaluation of efficacy of multispecific T-cell transfer in patients with chemo-refractory viral infections after allogeneic stem cell transplantationSecondary objectives:- Incidence and severity of newly occurring GvHD- Incidence…